ArticleAACE endocrinology and diabetes
Adrenal Insufficiency Due to Inhaled Etomidate in Electronic Cigarettes.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: A 33-year-old female presented with recurrent fainting. There was no hyperpigmentation, hirsutism, virilization, or oligomenorrhoea. She had not used antifungal medications, mitotane, metyrapone, or exogenous steroids. Her blood pressure was 135/83 mmHg when supine and 84/62 mmHg on standing. She was afebrile (36.8 °C) and her pulse rate was 81/min. Investigations showed: serum potassium 3.9 mmol/L (3.3 - 5.1), bicarbonate 25 mmol/L (21 - 32 mmol/L), peak cortisol on 250 mcg adrenocorticotropic hormone stimulation test 36 nmol/L, adrenocorticotropic hormone 29.7 pmol/L (1.6 - 13.9), 17-alpha-hydroxyprogesterone 3.6 nmol/L (0.3 - 3.3), dehydroepiandrosterone sulphate 2.6 umol/L (2.6 - 13.9), plasma aldosterone concentration 152 pmol/L (83 - 731), plasma renin activity 0.97 ng/ml/h (0.40 - 6.38), undetectable 21-hydroxylase antibody, and absence of adrenal hyperplasia or atrophy on computed tomography. Primary adrenal insufficiency was diagnosed. She was treated with hydrocortisone and dehydroepiandrosterone. Two months later, she admitted to using electronic cigarettes containing etomidate. Discussion: Adrenocortical suppression by inhaled etomidate presents variably. Most cases had glucocorticoid deficiency. More than half had mineralocorticoid excess. Two cases had hyperandrogenism. Our patient had low dehydroepiandrosterone sulphate which was not expected from 11-beta-hydroxylase inhibition by etomidate. Recovery from adrenocortical suppression was reported in 4 cases while 1 case had persistent adrenal insufficiency 5 months after abstinence. Adrenal insufficiency resolved after 8 months in our patient. Conclusion: Inhaled etomidate misuse is increasingly common and should be suspected in patients with unexplained adrenal insufficiency. Adrenocortical suppression by inhaled etomidate mimics rare forms of congenital adrenal hyperplasia and hypokalaemic periodic paralysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.